The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans
Open accessAbstract
Dengue virus co-circulates as four serotypes, and sequential infections with more than one serotype are common. One hypothesis for the increased severity seen in secondary infections is antibody-dependent enhancement (ADE) leading to increased replication in Fc receptor-bearing cells. In this study, we have generated a panel of human monoclonal antibodies to dengue virus. Antibodies to the structural precursor-membrane protein (prM) form a major component of the response. These antibodies are highly cross-reactive among the dengue virus serotypes and, even at high concentrations, do not neutralize infection but potently promote ADE. We propose that the partial cleavage of prM from the viral surface reduces the density of antigen available for viral neutralization, leaving dengue viruses susceptible to ADE by antibody to prM, a finding that has implications for future vaccine design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of the dengue virus envelope protein after membrane fusion
Modis, Y., Ogata, S., Clements, D., & Harrison, S. C. (2004) · Nature · doi:10.1038/nature02165 · Cited by 1,203
Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody
Halstead, S., & O'Rourke, E. (1977) · The Journal of Experimental Medicine · doi:10.1084/jem.146.1.201 · Cited by 804
RISK FACTORS IN DENGUE SHOCK SYNDROME: A PROSPECTIVE EPIDEMIOLOGIC STUDY IN RAYONG, THAILAND
SANGKAWIBHA, N., ROJANASUPHOT, S., AHANDRIK, S., VIRIYAPONGSE, S., JATANASEN, S., SALITUL, V., PHANTHUMACHINDA, B., & HALSTEAD, S. B. (1984) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113932 · Cited by 716
Innis, B. L., Nisalak, A., Nimmannitya, S., Kusalerdchariya, S., Chongswasdi, V., Suntayakorn, S., Puttisri, P., & Hoke, C. H. (1989) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1989.40.418 · Cited by 711
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
Prospects for a dengue virus vaccine
Whitehead, S. S., Blaney, J. E., Durbin, A. P., & Murphy, B. R. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1690 · Cited by 623
Structure of the Immature Dengue Virus at Low pH Primes Proteolytic Maturation
Yu, I.-M., Zhang, W., Holdaway, H. A., Li, L., Kostyuchenko, V. A., Chipman, P. R., Kuhn, R. J., Rossmann, M. G., & Chen, J. (2008) · Science · doi:10.1126/science.1153264 · Cited by 623
The Flavivirus Precursor Membrane-Envelope Protein Complex: Structure and Maturation
Li, L., Lok, S.-M., Yu, I.-M., Zhang, Y., Kuhn, R. J., Chen, J., & Rossmann, M. G. (2008) · Science · doi:10.1126/science.1153263 · Cited by 554
Structure of the Immature Dengue Virus at Low pH Primes Proteolytic Maturation
Yu, I.-M., Zhang, W., Holdaway, H. A., Li, L., Kostyuchenko, V. A., Chipman, P. R., Kuhn, R. J., Rossmann, M. G., & Chen, J. (2014) · Selected Papers of Michael G Rossmann with Commentaries · doi:10.1142/9789814513357_0047 · Cited by 436
Lai, C.-Y., Tsai, W.-Y., Lin, S.-R., Kao, C.-L., Hu, H.-P., King, C.-C., Wu, H.-C., Chang, G.-J., & Wang, W.-K. (2008) · Journal of Virology · doi:10.1128/jvi.00316-08 · Cited by 326
Cited by
Dengue: a continuing global threat
Guzman, M. G., Halstead, S. B., Artsob, H., Buchy, P., Farrar, J., Gubler, D. J., Hunsperger, E., Kroeger, A., Margolis, H. S., Martínez, E., et al. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2460 · Cited by 2,082
“The available data suggest that neutralizing antibodies are the major contributors to protective immunity 124,125 , however the role of the cellular immune response requires further study 123 .”
BackgroundAntibody-dependent enhancement of severe dengue disease in humans
Katzelnick, L. C., Gresh, L., Halloran, M. E., Mercado, J. C., Kuan, G., Gordon, A., Balmaseda, A., & Harris, E. (2017) · Science · doi:10.1126/science.aan6836 · Cited by 1,205
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms
Rothman, A. L. (2011) · Nature Reviews Immunology · doi:10.1038/nri3014 · Cited by 770
Guzman, M. G., Alvarez, M., & Halstead, S. B. (2013) · Archives of Virology · doi:10.1007/s00705-013-1645-3 · Cited by 738
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Lee, W. S., Wheatley, A. K., Kent, S. J., & DeKosky, B. J. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00789-5 · Cited by 676
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Wan, Y., Shang, J., Sun, S., Tai, W., Chen, J., Geng, Q., He, L., Chen, Y., Wu, J., Shi, Z., et al. (2020) · Journal of Virology · doi:10.1128/jvi.02015-19 · Cited by 662
From Vaccines to Memory and Back
Sallusto, F., Lanzavecchia, A., Araki, K., & Ahmed, R. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.008 · Cited by 637
Circular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
Beltramello, M., Williams, K. L., Simmons, C. P., Macagno, A., Simonelli, L., Quyen, N. T. H., Sukupolvi-Petty, S., Navarro-Sanchez, E., Young, P. R., de Silva, A. M., et al. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.007 · Cited by 592
Dejnirattisai, W., Wongwiwat, W., Supasa, S., Zhang, X., Dai, X., Rouvinski, A., Jumnainsong, A., Edwards, C., Quyen, N. T. H., Duangchinda, T., et al. (2015) · Nature Immunology · doi:10.1038/ni.3058 · Cited by 500
Self-citationBroadly Neutralizing Antiviral Antibodies
Corti, D., & Lanzavecchia, A. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095916 · Cited by 475
Halstead, S. B., Mahalingam, S., Marovich, M. A., Ubol, S., & Mosser, D. M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70166-3 · Cited by 409
Vasilakis, N., Cardosa, J., Hanley, K. A., Holmes, E. C., & Weaver, S. C. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2595 · Cited by 407
New insights into the immunopathology and control of dengue virus infection
Screaton, G., Mongkolsapaya, J., Yacoub, S., & Roberts, C. (2015) · Nature Reviews Immunology · doi:10.1038/nri3916 · Cited by 394
Self-citationIdentification of human neutralizing antibodies that bind to complex epitopes on dengue virions
de Alwis, R., Smith, S. A., Olivarez, N. P., Messer, W. B., Huynh, J. P., Wahala, W. M. P. B., White, L. J., Diamond, M. S., Baric, R. S., Crowe, J. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200566109 · Cited by 390
Tuiskunen Bäck, A., & Lundkvist, Å. (2013) · Infection Ecology & Epidemiology · doi:10.3402/iee.v3i0.19839 · Cited by 367
Dengue Fever: Causes, Complications, and Vaccine Strategies
Khetarpal, N., & Khanna, I. (2016) · Journal of Immunology Research · doi:10.1155/2016/6803098 · Cited by 363
The Human Antibody Response to Dengue Virus Infection
Wahala, W. M. P. B., & De Silva, A. M. (2011) · Viruses · doi:10.3390/v3122374 · Cited by 354
Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity
Reich, N. G., Shrestha, S., King, A. A., Rohani, P., Lessler, J., Kalayanarooj, S., Yoon, I.-K., Gibbons, R. V., Burke, D. S., & Cummings, D. A. T. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2013.0414 · Cited by 350
Receptors and routes of dengue virus entry into the host cells
Cruz-Oliveira, C., Freire, J. M., Conceição, T. M., Higa, L. M., Castanho, M. A. R. B., & Da Poian, A. T. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuu004 · Cited by 338
Dengue Antibody-Dependent Enhancement: Knowns and Unknowns
Halstead, S. B. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0022-2014 · Cited by 336
Adaptive immune responses to primary and secondary dengue virus infections
St. John, A. L., & Rathore, A. P. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0123-x · Cited by 327
Flavivirus Entry Receptors: An Update
Perera-Lecoin, M., Meertens, L., Carnec, X., & Amara, A. (2013) · Viruses · doi:10.3390/v6010069 · Cited by 323
Molecular Insight into Dengue Virus Pathogenesis and Its Implications for Disease Control
Diamond, M. S., & Pierson, T. C. (2015) · Cell · doi:10.1016/j.cell.2015.07.005 · Cited by 311
Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
Boldescu, V., Behnam, M. A. M., Vasilakis, N., & Klein, C. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.33 · Cited by 305
Chen, R., & Vasilakis, N. (2011) · Viruses · doi:10.3390/v3091562 · Cited by 301
Whitehorn, J., & Simmons, C. P. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.07.022 · Cited by 282
Lai, S., Huang, Z., Zhou, H., Anders, K. L., Perkins, T. A., Yin, W., Li, Y., Mu, D., Chen, Q., Zhang, Z., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0336-1 · Cited by 281
Antibodies to combat viral infections: development strategies and progress
Pantaleo, G., Correia, B., Fenwick, C., Joo, V. S., & Perez, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00495-3 · Cited by 279
Zika virus infection enhances future risk of severe dengue disease
Katzelnick, L. C., Narvaez, C., Arguello, S., Lopez Mercado, B., Collado, D., Ampie, O., Elizondo, D., Miranda, T., Bustos Carillo, F., Mercado, J. C., et al. (2020) · Science · doi:10.1126/science.abb6143 · Cited by 271
Zika Virus Structure, Maturation, and Receptors
Sirohi, D., & Kuhn, R. J. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix515 · Cited by 265
Degrees of maturity: the complex structure and biology of flaviviruses
Pierson, T. C., & Diamond, M. S. (2012) · Current Opinion in Virology · doi:10.1016/j.coviro.2012.02.011 · Cited by 265
The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design
Rey, F. A., Stiasny, K., Vaney, M., Dellarole, M., & Heinz, F. X. (2018) · EMBO reports · doi:10.15252/embr.201745302 · Cited by 259
Rapid and Massive Virus-Specific Plasmablast Responses during Acute Dengue Virus Infection in Humans
Wrammert, J., Onlamoon, N., Akondy, R. S., Perng, G. C., Polsrila, K., Chandele, A., Kwissa, M., Pulendran, B., Wilson, P. C., Wittawatmongkol, O., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06075-11 · Cited by 257
Fc receptors in antibody‐dependent enhancement of viral infections
Taylor, A., Foo, S., Bruzzone, R., Vu Dinh, L., King, N. J. C., & Mahalingam, S. (2015) · Immunological Reviews · doi:10.1111/imr.12367 · Cited by 255
Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M. S., Luo, G., Li, W., Zhong, G., et al. (2020) · doi:10.1101/2020.04.10.036418 · Cited by 140
Monoclonal antibodies for prophylactic and therapeutic use against viral infections
Both, L., Banyard, A. C., van Dolleweerd, C., Wright, E., Ma, J. K.-C., & Fooks, A. R. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.01.025 · Cited by 107
mRNA Vaccines against Flaviviruses
Wollner, C. J., & Richner, J. M. (2021) · Vaccines · doi:10.3390/vaccines9020148 · Cited by 44
A Single Dose of NILV-Based Vaccine Provides Rapid and Durable Protection against Zika Virus
Ku, M. W., Anna, F., Souque, P., Petres, S., Prot, M., Simon-Loriere, E., Charneau, P., & Bourgine, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.016 · Cited by 29
Metadata
- Authors
- Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T., Supasa, S., Chawansuntati, K., Malasit, P., Mongkolsapaya, J., & Screaton, G.
- Venue
- Science
- Published
- 2010-05-07
- Volume
- 328
- Issue
- 5979
- Pages
- 745-748
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2052669763
- Cited by
- 943
- References
- 15
- FWCI
- 59.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.